PropertyValue
?:definition
  • A coronavirus vaccine composed of a recombinant form of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike protein (SP) combined with a proprietary polysaccharide-based vaccine adjuvant, Advax-CpG55.2, with potential immunomodulating and anti-COVID-19 activities. Upon administration of Covax-19, the SARS-CoV-2 SP activates the immune system to produce anti-SARS-CoV-2 SP antibodies and T-cell responses against SARS-CoV-2 SP. The antibodies recognize the SP and kill SARS-CoV-2. This prevents SARS-CoV-2 infection. SP, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus. The proprietary adjuvant strongly stimulates both T-cell and antibody immune responses when combined with the recombinant SARS-CoV-2 SP.
?:hasCUIAnnotation
?:hasGeneratedBy
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C5420359_NCI>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C5420359_NCI>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all